Geraldo Saavedra, MD
Endocrinology, Diabetes & Metabolism · Whitehall, PANPI 1700861630
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $571,033 of the $698,116 with a category attached, or 81.8%. 60 manufacturers reported payments, led by Lilly USA, LLC at 52.4% of the total. Reporting peaked in 2019 at $166,606 and has fallen 51.2% since, to $81,362 in 2025. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,125 payments — averaging $223.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$366K
- Novo Nordisk$129K
- Boehringer Ingelheim$39K
- Sanofi-aventis U.S. LLC$33K
- Insulet Corporation$28K
- AstraZeneca$22K
- plus $81K from 54 others
What the payments were for
- Consulting fees$6,1751%
- Speaking & faculty fees$571,03382%
- Travel & lodging$54,4958%
- Food & beverage$65,8859%
- Education$4680%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$132,888
- TRULICITY$126,969
- JARDIANCE$105,907
- Ozempic$64,466
- RYBELSUS$46,950
- Omnipod$27,528
- SOLIQUA 100/33$21,563
- FARXIGA$18,342
- AFREZZA$15,131
- NEXLIZET$13,616
- NEXLETOL$13,616
- TOUJEO$11,381
- CeQur Simplicity$7,541
- Tresiba$5,349
- Minimed 770G System$3,050
- Synthroid$2,874
- t:slim X2 Insulin Pump with Control-IQ$2,011
- Repatha$1,613
- Kerendia$1,214
- iLet Bionic Pancreas$1,032
How this compares
$698,116 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 926 | $998,973 |
| JardianceEmpagliflozin | 647 | $812,363 |
| TrulicityDulaglutide | 702 | $771,888 |
| KorlymMifepristone | 18 | $711,179 |
| OzempicSemaglutide | 564 | $699,064 |
| RecorlevLevoketoconazole | 12 | $693,511 |
| KerendiaFinerenone | 413 | $560,286 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 185 | $245,730 |
| FarxigaDapagliflozin Propanediol | 216 | $224,836 |
| SynjardyEmpagliflozin/Metformin Hcl | 226 | $195,293 |
| AfrezzaInsulin Regular, Human | 66 | $187,032 |
| ProliaDenosumab | 112 | $182,556 |
| Gvoke Hypopen 2-PackGlucagon | 280 | $170,308 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 165 | $170,160 |
| LinzessLinaclotide | 137 | $157,793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $365,570 | $1,770,8611,628 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Glyxambi, Tradjenta | $39,225 | $1,352,1011,138 claims |
| Novo NordiskOzempic, Novolog | $129,003 | $739,469709 claims |
| Corcept TherapeuticsKorlym | $2,214 | $711,17918 claims |
| Xeris Pharmaceuticals, Inc.Recorlev | $2,197 | $693,51112 claims |
| BayerKerendia | $1,914 | $560,286413 claims |
| AmgenProlia, Evenity (2 Syringes) | $4,842 | $245,118138 claims |
| AstraZenecaFarxiga | $21,965 | $224,836216 claims |
| Mannkind CorporationAfrezza | $17,460 | $187,03266 claims |
| AbbVieLinzess | $5,427 | $157,793137 claims |
| NovartisLeqvio | $667 | $74,31423 claims |
| MerckJanumet Xr, Januvia | $514 | $65,41055 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Whitehall
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
- Mitchell LazarPhiladelphia$358K
- Vishal DattaCollegeville$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.